Skip to main content
SupplementScience

Palmitoylethanolamide (PEA) Research & Evidence

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

Evidence Level

Moderate

PEA was first identified in the 1950s and its analgesic properties were studied by Nobel laureate Rita Levi-Montalcini. A comprehensive 2017 meta-analysis by Paladini et al. (12 RCTs, n=1,188) confirmed significant pain reduction across chronic pain conditions. PEA acts through PPAR-alpha activation (reducing NF-kB-mediated inflammation) and mast cell stabilization (the ALIA mechanism described by Levi-Montalcini). Unlike cannabinoids, PEA does not bind CB1 or CB2 receptors and has no psychoactive effects. It enhances anandamide signaling indirectly via FAAH inhibition. The micronized/ultra-micronized forms are critical for efficacy due to PEA's poor solubility in standard powder form. Its remarkable safety profile — no known drug interactions, no psychoactive effects, no tolerance — makes it uniquely suitable for long-term pain management.

Evidence by Condition

ConditionStudied DoseEvidence
Chronic pain600mg twice daily (1,200mg/day)Moderate
Neuropathic pain600mg twice daily for 3 weeks, then 600mg once dailyModerate
General anti-inflammatory300-600mg dailyEmerging
Full Palmitoylethanolamide (PEA) Guide

References

  1. (). Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician.
  2. (). Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. Journal of Pain Research. DOI
  3. (). The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. British Journal of Pharmacology. DOI